达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松治疗新诊断多发性骨髓瘤:GRIFFIN研究血管血栓事件分析
GRIFFIN研究事后分析评估达雷妥尤单抗联合来那度胺/硼替佐米/地塞米松(D-RVd)对比RVd方案的血栓栓塞事件(VTE)。安全性人群中D-RVd组VTE发生率10.1%,RVd组15.7%;D-RVd组首次VTE中位时间更长(305天 vs 119天)。加用达雷妥尤单抗未增加VTE发生率,但队列累积VTE发生率较高且抗血栓预防使用欠佳。
要点
- D-RVd组VTE发生率10.1%,RVd组15.7%,加用达雷妥尤单抗未增加VTE风险
- D-RVd组首次VTE中位时间305天,长于RVd组的119天
- 抗血栓预防使用率D-RVd组84.8%,RVd组83.3%,但VTE发生时预防使用仅60.0%和68.8%
核心结论
- 在新诊断适合自体干细胞移植的多发性骨髓瘤患者中,RVd方案加用达雷妥尤单抗未增加VTE发生率,但该队列累积VTE发生率相对较高且抗血栓预防使用欠佳。
研究设计与样本
- 随机2期GRIFFIN研究(ClinicalTrials.gov标识NCT02874742)的事后分析,评估RVd±达雷妥尤单抗(D)治疗新诊断多发性骨髓瘤患者的VTE。
- 治疗流程包括D-RVd/RVd诱导、大剂量治疗和自体干细胞移植、D-RVd/RVd巩固及最长2年来那度胺维持治疗±达雷妥尤单抗。
- 依据国际骨髓瘤工作组指南推荐VTE预防(至少阿司匹林每日≥162 mg)。
主要发现
- D-RVd组VTE发生率为10.1%,RVd组为15.7%;2-4级VTE发生率分别为9.1%和14.7%。
- D-RVd组首次VTE中位发生时间较RVd组长(305天 vs 119天)。
- 抗血栓预防使用率两组相似:D-RVd组84.8% vs RVd组83.3%。
- 在发生VTE的患者中,首次VTE发生时预防使用率D-RVd组为60.0%,RVd组为68.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) that investigated lenalidomide/bortezomib/dexamethasone (RVd) ± daratumumab (D). Patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplantation (ASCT) received D-RVd/RVd induction, high-dose therapy and ASCT, D-RVd/RVd consolidation and up to 2 years of lenalidomide maintenance therapy ± D. VTE prophylaxis was recommended (at least aspirin, ≥162 mg daily) in accordance with International Myeloma Working Group guidelines. In the safety population (D-RVd, n = 99; RVd, n = 102), VTEs occurred in 10.1% of D-RVd patients and 15.7% of RVd patients; grade 2-4 VTEs occurred in 9.1% and 14.7%, respectively. Median time to the first onset of VTE was longer for D-RVd versus RVd patients (305 days vs 119 days). Anti-thrombosis prophylaxis use was similar between arms (D-RVd, 84.8% vs RVd, 83.3%); among patients with VTEs, prophylaxis use at time of first VTE onset was 60.0% for D-RVd and 68.8% for RVd. In summary, the addition of daratumumab to RVd did not increase the incidence of VTEs, but the cumulative VTE incidence was relatively high in this cohort and anti-thrombotic prophylaxis use was suboptimal.
引用
- Sborov DW, Baljevic M, Reeves B, et al. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol. 2022. PMID: 36111391. doi:10.1111/bjh.18432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。